A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer

BACKGROUND: The combination of sorafenib (vascular endothelial growth factor receptor 2 inhibitor) and sirolimus (mammalian target of rapamycin inhibitor) might work synergistically. METHODS: A phase I dose-escalation study with sorafenib twice a day (b.i.d.) and sirolimus once daily (q.d.) was perf...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Desar, I M E, Timmer-Bonte, J N H, Burger, D M, van der Graaf, W T A, van Herpen, C M L
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2010
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2994217/
https://ncbi.nlm.nih.gov/pubmed/21045832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605777
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki